AEON AEON Biopharma, Inc.

NYSE Pharmaceutical Preparations DE CIK: 0001837607
AI RATING
STRONG_SELL
88% Confidence

Investment Thesis

AEON exhibits critical balance sheet insolvency with negative stockholders equity of -$16.8M and total liabilities exceeding assets. Negative operating cash flow of -$2.6M combined with a current ratio of 0.99x indicates severe liquidity stress and an unsustainable burn rate, with only ~2-3 years of cash runway remaining.

Strengths

  • + Retains $6.2M in cash providing near-term operational buffer
  • + Minimal capital expenditure ($4K) suggests focus on asset-light development model
  • + Recent insider activity (5 Form 4 filings) indicates ongoing management engagement

Risks

  • ! Negative stockholders equity of -$16.8M indicates technical insolvency and balance sheet failure
  • ! Negative operating cash flow of -$2.6M with no revenue reported suggests unsustainable cash burn
  • ! Current ratio of 0.99x reflects immediate liquidity crisis with current liabilities exceeding current assets
  • ! Severe dilution risk from necessary capital raises to avoid bankruptcy
  • ! Pre-revenue/early-stage development company with high probability of going concern failure

Key Metrics to Watch

Financial Metrics

Revenue
N/A
Net Income
-11.8M
EPS (Diluted)
$-0.29
Free Cash Flow
-2.6M
Total Assets
8.6M
Cash
6.2M

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -136.7%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
0.99x
Quick Ratio
0.99x
Debt/Equity
N/A
Debt/Assets
294.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-15T08:30:49.446466 | Data as of: 2026-03-31 | Powered by Claude AI